(EXAS) EXACT Sciences - Ratings and Ratios

Exact Sciences Corporation (NASDAQ:EXAS) is a leading developer of innovative cancer screening and diagnostic solutions. The company is best known for Cologuard, the first FDA-approved, non-invasive stool-based DNA screening test for colorectal cancer (CRC). Cologuard detects specific DNA mutations and hemoglobin biomarkers associated with CRC and pre-cancerous lesions, offering a patient-friendly alternative to traditional screening methods like colonoscopy. Since its approval in 2014, Cologuard has become a cornerstone of Exact Sciences commercial portfolio, with widespread adoption in the U.S. and growing international presence.

Beyond Cologuard, Exact Sciences offers a portfolio of precision oncology tests, including the Oncotype DX suite of products. These tests provide personalized insights into cancer recurrence risk and treatment response for breast and colon cancers. The company also offers the OncoExTra test for advanced cancer patients, enabling tumor profiling to guide targeted therapy selection. Additionally, Exact Sciences provides Riskguard, a hereditary cancer risk assessment test, to help individuals understand their genetic predisposition to certain cancers. These offerings are supported by partnerships with leading medical institutions, including Mayo Clinic and Johns Hopkins University.

Exact Sciences pipeline is focused on expanding its capabilities in cancer screening, early diagnosis, and treatment selection. The company is investing in next-generation technologies for risk assessment, recurrence monitoring, and metastatic disease management. Its research and development efforts aim to integrate advanced genomics, machine learning, and biomarker discovery to improve cancer outcomes. With a strong intellectual property portfolio and strategic collaborations, Exact Sciences is well-positioned to maintain its leadership in the precision medicine space.

Headquartered in Madison, Wisconsin, Exact Sciences has grown significantly since its founding in 1995. The company has established itself as a pioneer in non-invasive cancer diagnostics, with a market capitalization of approximately $7.7 billion as of recent data. Its commitment to improving patient outcomes through innovative testing solutions has made it a key player in the biotechnology industry.